Citizens Capital Markets:重申Acrivon Therapeutics(ACRV.US)评级,由优于大市调整至优于大市评级,目标价由17.00美元调整至17.00美元。Acrivon Therapeutics(ACRV.US)公司简介:Acrivon Therapeutics Inc是一家临床阶段的生物制药公司,开发肿瘤药物,利用其基于蛋白质组学的患者响应器识别平台,将其...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.